Compare Iron Mountain Inc (IRM) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iron Mountain Inc vs Tango Therapeutics Inc. — how do they compare? Iron Mountain Inc trades at $111.8 (market cap $33.00B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Iron Mountain Inc is far larger — about 8.8× Tango Therapeutics Inc.'s market cap, and Iron Mountain Inc pays a 3.12% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iron Mountain Inc for 80 Days and Tango Therapeutics Inc. for 0 Days on average.
| IRM | TNGX | |
|---|---|---|
Market Cap | $33.00B | $3.74B |
Volume | 1,075,916 | 3,438,781 |
Sector | Real Estate | Health |
52-Week High | $133.06 | $32.90 |
52-Week Low | $78.86 | $7.50 |
Typical Hold Time | 80 Days | 0 Days |
Enterprise Value | $52.41B | $2.76B |
Dividend Yield | 3.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Iron Mountain (IRM) trades at $114.60, down 0.43% on the day, with a neutral technical signal. The stock shows strong analyst support with a 66.7% buy rating and a consensus price target of $142.75, implying significant upside. Recent earnings have consistently beaten expectations, and the company is expanding its data center pipeline and digital solutions, as highlighted in recent news. However, high debt levels and a declining net income margin present fundamental concerns.
The outlook is mixed: growth in data centers and digital services offers opportunity, but elevated valuation ratios and leverage pose risks. Investor sentiment is cautiously optimistic, driven by strategic initiatives, though execution and macroeconomic factors remain key watchpoints for stock performance.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
